Details of the Drug

General Information of Drug (ID: DMRI6YT)

Drug Name
BI 836880
Indication
Disease Entry ICD 11 Status REF
Neoplasm 2A00-2F9Z Phase 1 [1]
Wet age-related macular degeneration 9B78.3Z Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
D62LKT

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Blocker [3]
Vascular endothelial growth factor (VEGF) TT9HKJA VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN Blocker [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Neoplasm
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin-2 (ANGPT2) DTT ANGPT2 3.47E-04 -0.31 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03972150) A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03861234) A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
6 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
7 Company report (Roche pipeline: July 27, 2017)
8 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
9 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
10 Clinical pipeline report, company report or official report of CovX (2011).
11 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
14 Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
15 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
16 National Cancer Institute Drug Dictionary (drug id 43234).
17 ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
18 Clinical pipeline report, company report or official report of Fujifilm.
19 Clinical pipeline report, company report or official report of Kodiak Sciences.
20 Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
21 Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
22 Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
23 Clinical pipeline report, company report or official report of Avalanche Biotechnologies.